<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833322</url>
  </required_header>
  <id_info>
    <org_study_id>NEUROLOGIAHRI-01</org_study_id>
    <nct_id>NCT04833322</nct_id>
  </id_info>
  <brief_title>Galactose Supplementation for the Treatment of MOGHE</brief_title>
  <acronym>GATE</acronym>
  <official_title>Galactose Supplementation for the Treatment of Patients With Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE): a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ruber Internacional</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ruber Internacional</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy&#xD;
      (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental&#xD;
      disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2)&#xD;
      brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic&#xD;
      variants improve with galactose supplementation. Therefore, the investigators aim to&#xD;
      elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental&#xD;
      outcomes in patients with MOGHE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Before-and-after pilot clinical trial with a single group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure frequency</measure>
    <time_frame>6 months</time_frame>
    <description>Seizure diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epileptiform activity at EEG</measure>
    <time_frame>6 months</time_frame>
    <description>Epileptiform activity quantification (per epoch)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Teacher and Parent Rating Scale (SNAP-IV) and Conners Continuous Performance Test (CPT-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated with Wechsler Intelligence Scale for Children (WISC-IV) and Behavior Rating Inventory of Executive Function-2 (BRIEF-2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Refractory Epilepsy</condition>
  <condition>SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation</condition>
  <arm_group>
    <arm_group_label>Single arm group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galactose supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-Galactose</intervention_name>
    <description>Galactose supplementation, once per day, up to 1.5g/kg per day</description>
    <arm_group_label>Single arm group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MOGHE diagnosis at histopathological examination of the epilepsy surgery tissue.&#xD;
&#xD;
          -  Epilepsy refractoriness or ongoing epileptiform activity at EEG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to galactose or supplement components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Aledo-Serrano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ruber Internacional</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel Aledo-Serrano, MD PhD</last_name>
    <phone>0034-913875250</phone>
    <email>aaledo@neurologiaclinica.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Rodriguez</last_name>
    <phone>0034-913875250</phone>
    <email>ensayosepi@neurologiaclinica.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel A Aledo-Serrano, MD PhD</last_name>
      <phone>0034-913875250</phone>
      <email>aaledo@neurologiaclinica.es</email>
    </contact>
    <investigator>
      <last_name>Angel Aledo-Serrano, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Gil-Nagel, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ruber Internacional</investigator_affiliation>
    <investigator_full_name>Angel Aledo-Serrano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

